Anixa Biosciences (ANIX) announced that the United States Patent and Trademark Office, USPTO, has issued a Notice of Allowance for a key patent application covering its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II, AMHR2, a promising target for ovarian cancer prevention and treatment.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
- Anixa Biosciences Holds Annual Stockholder Meeting 2025
- Anixa Biosciences initiated with a Buy at Maxim
- Anixa doses first patient in third cohort of Phase 1 clinical trial of CAR-T
- Anixa Biosciences: Advancing CAR-T Therapy and Cancer Vaccines with Strategic Trial Amendments and Robust Financial Position
- Anixa Biosciences announces approval of protocol amendment for CAR-T trial